Herbs and dietary supplement-induced liver injury (HILI) is the leading cause of drug-induced liver injury in China. Among different hepatotoxic herbs, the pyrrolizidine alkaloid (PA)-producing herb Gynura japonica contributes significantly to HILI by inducing hepatic sinusoidal obstruction syndrome (HSOS), a liver disorder characterized by hepatomegaly, hyperbilirubinemia, and ascites. In China, G. japonica has been used as one of the plant species for Tu-San-Qi and is often misused with non-PA-producing Tu-San-Qi (Sedum aizoon) or even San-Qi (Panax notoginseng) for self-medication. It has been reported that over 50% of HSOS cases are caused by the intake of PA-producing G. japonica. In this review, we provide comprehensive information to distinguish these Tu-San-Qi-related herbal plant species in terms of plant/medicinal part morphologies, medicinal indications, and chemical profiles. Approximately 2156 Tu-San-Qi-associated HSOS cases reported in China from 1980 to 2019 are systematically reviewed in terms of their clinical manifestation, diagnostic workups, therapeutic interventions, and outcomes. In addition, based on the application of our developed mechanism-based biomarker of PA exposure, our clinical findings on the definitive diagnosis of 58 PA-producing Tu-San-Qi-induced HSOS patients are also elaborated. Therefore, this review article provides the first comprehensive report on 2214 PA-producing Tu-San-Qi (G. japonica)-induced HSOS cases in China, and the information presented will improve public awareness of the significant incidence of PA-producing Tu-San-Qi (G. japonica)-induced HSOS and facilitate future prevention and better clinical management of this severe HILI.
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Chalasani NP, Hayashi PH, Bonkovsky HL, Herbert L, Navarro VJ, Lee WM, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950–66.
Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4:489–99.
Navarro VJ, Senior JR. Drug-related hepatotoxicity. N. Engl J Med. 2006;354:731–9.
Shen T, Liu YX, Shang J, Xie Q, Li J, Yan M, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology. 2019;156:2230–41.
Valla DC, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2016;40:378–85.
Wang Y, Qiao D, Li Y, Xu F. Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study. BMC Gastroenterol. 2018;18:156.
Wang JY, Gao H. Tusanqi and hepatic sinusoidal obstruction syndrome. J Dig Dis. 2014;15:105–7.
Edgar JA, Molyneux RJ, Colegate SM. Pyrrolizidine alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol. 2015;28:4–20.
Lin G, Wang JY, Li N, Li M, Gao H, Ji Y, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2011;54:666–73.
Fu PP, Xia QS, Lin G, Chou MW. Pyrrolizidine alkaloids–genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev. 2004;36:1–55.
Mattocks AR. Chemistry and toxicology of pyrrolizidine alkaloids. London: Academic Press; 1986.
Smith LW, Culvenor CC. Plant sources of hepatotoxic pyrrolizidine alkaloids. J Nat Prod. 1981;44:129–52.
Kakar F, Akbarian Z, Leslie T, Mustafa ML, Watson J, Egmond HPV, et al. An outbreak of hepatic veno-occlusive disease in western Afghanistan associated with exposure to wheat flour contaminated with pyrrolizidine alkaloids. J Toxicol. 2010;2010:313280.
Edgar JA, Smith LW. Transfer of pyrrolizidine alkaloids into eggs: food safety implications. ACS Symp Ser. 1999;8:118–28.
Kempf M, Heil S, Hasslauer I, Schmidt L, Ohe Kvd, Theuring C, et al. Pyrrolizidine alkaloids in pollen and pollen products. Mol Nutr Food Res. 2010;54:292–300.
Panter KE, James LF. Natural plant toxicants in milk: a review. J Anim Sci. 1990;68:892–904.
Willmot FC, Robertson GW. Senecio disease or cirrhosis of the liver due to Senecio poisoning. Lancet. 1920;2:848.
Ma J, Ruan J, Chen X, Li D, Yao S, Fu PP, et al. Pyrrole-hemoglobin adducts, a more feasible potential biomarker of pyrrolizidine alkaloid exposure. Chem Res Toxicol. 2019;32:1027–39.
Cooperative Group for Health and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolizidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing). J Clin Hepatol. 2017;33:1627–37.
Ruan JQ, Gao H, Li N, Xue JY, Chen J, Ke CQ, et al. Blood pyrrole-protein adducts-a biomarker of pyrrolizidine alkaloid-induced liver injury in humans. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015;33:404–21.
Yang MB, Ruan JQ, Gao H, Li N, Ma J, Xue JY, et al. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol. 2017;91:3913–2925.
Wang XX, Qi XS, Guo XZ. Tusanqi-related sinusoidal obstruction syndrome in China: a systematic review of the literatures. Medicine. 2015;94:e942.
Commission of Chinese Materia Medica. Materia Medica of China. Shanghai (China): Shanghai Scientific and Technical Publishers; 1999a; 3: p 765–7.
Commission of Chinese Materia Medica. Materia Medica of China. Shanghai (China): Shanghai Scientific and Technical Publishers; 1999b; 5: p 839–50.
Commission of Chinese Materia Medica. Materia Medica of China. Shanghai (China): Shanghai Scientific and Technical Publishers; 1999c; 7: p 855–7.
Flora of China Editorial Committee. Beijing (China): Flora of China. Science Press; 1999a; 78: p 128.
Flora of China Editorial Committee. Beijing (China): Flora of China. Science Press; Flora of China. Science Press; 1999b; 78: p 312–3.
Gynura japonica (Thunb.) Juel. World Flora Online. 2020. http://www.worldfloraonline.org/taxon/wfo-0000011089.
Xiong AZ, Shao YL, Fang LX, Yang X, Zhang SC, Zheng J, et al. Comparative analysis of toxic components in different medicinal parts of Gynura japonica and its toxicity assessment on mice. Phytomedicine. 2019;54:77–88.
Hou JG. Veno-occlusive disease of the liver with report of 2 cases. Zhonghua Nei Ke Za Zhi. 1980;19:187–91.
Zhang M, Zhuge YZ, Chen J. Hepatic venous pressure gradient and transjugular liver biopsy confirms a case of atypical hepatic venoocclusive disease. Chin J Gastroenterol. 2013;33:636–7.
Zhuge YZ, Liu YL, Xie WF, Zou XP, Xu JM, Wang JY, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol. 2019;34:634–42.
Beihany AA, Omar HA, Sahovic E, Chaudhri N, Mohareb FA, Sharif FA, et al. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transpl. 2008;41:287–91.
Narita M, Hatano E, Tamaki N, Yamanaka K, Yanagida A, Nagata H, et al. Dai-kenchu-to attenuates rat sinusoidal obstruction syndrome by inhibiting the accumulation of neutrophils in the liver. J Gastroenterol Hepatol. 2009;24:1051–7.
Zhu HY, Chu Y, Huo JR, Chen Z, Yang L. Effect of prednisone on transforming growth factor-β1, connective tissue growth factor, nuclear factor-κB p65 and tumor necrosis factor-α expression in a murine model of hepatic sinusoidal obstruction syndrome induced by Gynura segetum. Hepatol Res. 2011;41:795–803.
Zhuge YZ, Wang Y, Zhang F, Zhu CK, Zhang W, Zhang M, et al. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease. Liver Int. 2018;38:1867–74.
Deleve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49:1729–64.
Rubia J, Carral A, Montes H, Urquijo JJ, Sanz GF, Sanz MA. Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt (TIPS). Haematologica. 1996;81:536–9.
Valla DC. Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome. Gut. 2008;57:1469–78.
Corbacioglu S, Kernan N, Lehmann L, Brochstein J, Revta C, Grupp S, et al. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Expert Rev Hematol. 2012;5:291–302.
Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163:444–57.
Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transpl. 2008;41:229–37.
Cao Y, Colegate SM, Edgar JA. Safety assessment of food and herbal products containing hepatotoxic pyrrolizidine alkaloids: interlaboratory consistency and the importance of N-oxide determination. Phytochem Anal. 2008;19:526–33.
Molyneux RJ, Gardner DL, Colegate SM, Edgar JA. Pyrrolizidine alkaloid toxicity in livestock: a paradigm for human poisoning? Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2011;28:293–307.
Williams MT, Warnock BJ, Betz JM, Beck JJ, Gardner DR, Lee ST, et al. Detection of high levels of pyrrolizidine-N-oxides in the endangered plant Cryptantha crassipes (Terlingua Creek cat’s-eye) using HPLC-ESI-MS. Phytochem Anal. 2011;22:532–40.
Edgar JA, Roeder E, Molyneux RJ. Honey from plants containing pyrrolizidine alkaloids: a potential threat to health. J Agric Food Chem. 2002;50:2719–30.
Fu PP, Xia QS, Chou MW, Lin G. Detection, hepatotoxicity, and tumorigenicity of pyrrolizidine alkaloids in Chinese herbal plants and herbal dietary supplements. J Food Drug Anal. 2007;15:400–15.
Stegelmeier BL, Edgar JA, Colegate SM, Gardner DR, Schoch TK, Coulombe RA, et al. Pyrrolizidine alkaloid plants, metabolism and toxicity. J Nat Toxins. 1999;8:95–116.
Yang MB, Ma J, Ruan JQ, Ye Y, Fu PP, Lin G. Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids. Arch Toxicol. 2019;93:2197–209.
Lu Y, Ma J, Song ZJ, Ye Y, Fu PP, Lin G. The role of formation of pyrrole-ATP synthase subunit beta adduct in pyrrolizidine alkaloid-induced hepatotoxicity. Arch Toxicol. 2018;92:3403–14.
Yang MB, Ma J, Ruan JQ, Zhang CY, Ye Y, Fu PP, et al. Absorption difference between hepatotoxic pyrrolizidine alkaloids and their N-oxides-mechanism and its potential toxic impact. J Ethnopharmacol. 2020;249:112421.
Gao H, Ruan JQ, Chen J, Li N, Ke CQ, Ye Y, et al. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Devel Ther. 2015;9:4861–8.
Gao H, Li N, Wang JY, Zhang SC, Lin G. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis. 2012;13:33–39.
European Association for the Study of the Liver (EASL), Clinical Practice Guideline Panel. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70:1222–61.
Ou PC, Chen Y, Li BZ, Zhang M, Liu XY, Li FF, et al. Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital. Springerplus. 2015;4:1–8.
Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11:221–41.
Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 2013;4:1–10.
Meunier L, Larrey D. Drug-induced liver injury: bomarkers, requirements, candidates, and validation. Front Pharmacol. 2019;10:1482.
Zhang C, Jiang M, Zhang G, Bian ZX, Lu AP. Progress and perspectives of biomarker discovery in Chinese medicine research. Chin J Integr Med. 2014;9:1–9.
Ma J, Xia QS, Fu PP, Lin G. Pyrrole-protein adducts–A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity. J Food Drug Anal. 2018;26:965–72.
National Center for Environmental Health, 2012. https://www.cdc.gov/nceh/stories/ethiopia.html
Cong WH, Xin QQ, Gao YQ. RE: Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology. 2019;157:1438–9.
Tang J, Hattori M. Pyrrolizidine alkaloids-containing Chinese medicines in the Chinese Pharmacopoeia and related safety concerns. Yao Xue Xue Bao. 2011;46:762–72.
Fu PP, Yang YC, Xia QS, Chou MW, Cui YY, Lin G. Pyrrolizidine alkaloids-tumorigenic components in Chinese herbal medicines and dietary supplements. J Food Drug Anal. 2002;10:198–211.
Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Beijing: Chinese Medical Science and Technology Press; Volume 1, 2015.
The present study was supported by the Research Grant Council of Hong Kong (GRF Grant no. 14111816 and 14106318), the CUHK Project Impact Enhancement Fund (PIEF Grant No. 3133029) and the CUHK Direct Grant (Grant No. 4054503). This article is not an official USA Food and Drug Administration (FDA) guidance or policy statement. No official support or endorsement by the USA FDA is intended or should be inferred.
The authors declare no competing interests.
About this article
Cite this article
Zhu, L., Zhang, Cy., Li, Dp. et al. Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. Acta Pharmacol Sin 42, 1212–1222 (2021). https://doi.org/10.1038/s41401-020-00553-9
- herb-induced liver injury
- hepatic sinusoidal obstruction syndrome
- pyrrolizidine alkaloids
- Gynura japonica
Archives of Toxicology (2021)
Clinical application of pyrrole–hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans
Archives of Toxicology (2021)